Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Morphine sulfate, oxycodone, and oxymorphone are all potent opioid analgesics used for the management of moderate to severe pain. Each acts primarily as an agonist at the mu-opioid receptor in the central nervous system, leading to analgesia, euphoria, and respiratory depression. Morphine is a naturally occurring opiate; oxycodone is a semisynthetic opioid derived from thebaine; and oxymorphone is a semisynthetic derivative of morphine with higher potency and greater lipophilicity than morphine. All three drugs are controlled substances due to their high potential for abuse and dependence. They are indicated for pain severe enough to require daily, around-the-clock opioid treatment when alternative treatments are inadequate[3][4][6][8].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Morphine sulfate + oxycodone + oxymorphone.